Physician profile

Eric C Trautmann

Family Medicine · Rockford, IL

NPI 1477599835

$2,330.98

in general payments reported to CMS, 2019-2025

24 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $282.05 2019-2021
Lilly USA, LLC $274.32 2019-2022
Novo Nordisk INC $236.50 2019-2021
Boehringer Ingelheim Pharmaceuticals, INC. $229.55 2019-2021
Pfizer INC. $225.48 2019-2020
Astrazeneca Pharmaceuticals LP $223.76 2019-2021
Merck Sharp & Dohme LLC $131.53 2019-2021
Amgen INC. $118.67 2019-2020
Novartis Pharmaceuticals Corporation $103.88 2019
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $84.08 2019-2020
Allergan, INC. $65.65 2019
Supernus Pharmaceuticals, INC. $54.81 2019-2021
Janssen Pharmaceuticals, INC $45.66 2019
Astellas Pharma US INC $42.95 2019
E.R. Squibb & Sons, L.L.C. $29.51 2020
Show all 24 companies
CompanyGeneral paymentsYearsTop products
Shionogi INC $27.22 2019
Mylan Specialty L.P. $26.45 2019
Abbvie INC. $23.09 2021
Otsuka America Pharmaceutical, INC. $22.11 2019
Sanofi Pasteur INC. $20.28 2019
Sunovion Pharmaceuticals INC. $17.00 2019
Shire North American Group INC $16.35 2019
Abbott Laboratories $16.18 2020
Ascensia Diabetes Care US INC. $13.90 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Eric C Trautmann

$2,330.98

in general payments reported 2019-2025

Years
2019-2022
Top company
Glaxosmithkline, LLC.

https://glasscript.com/doctor/111922/eric-c-trautmann

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.